Syngene Ltd

  Overview

Syngene has a strong patent portfolio in the gene-based diagnostic technology known as in situ hybridisation. It is also building a research portfolio in gene based diagnostics and therapeutics, including a collaborative program with the Howard Florey Institute in Melbourne based on novel approaches to enhance the uptake of therapeutic compounds to various tissues, including the brain.

Syngene is also a major shareholder in the listed Antisense Therapeutics Limited.

  Competitive Advantages

Strong IP position and high quality research facilities and personnel based at the Florey Institute.

  Technology

Focus is on gene based diagnostics and therapeutics, leveraging patent portfolio.

  Corporate Alliances/Partnerships

Partners

Several licensees of technology, including Roche Diagnostics and Novocastra Laboratories.

Partnering Opportunities

Licensing opportunities for in situ hybridisation and novel methods for conjugation to oligonucleotides.

Partnering Needs

Principally licensing, at this stage, but other partnering opportunities will evolve as research projects mature.

back